Finally, the DIAMOND trial demonstrated that the concurrent use of MRA and patiromer in patients with HFrEF and renin–angiotensin–aldosterone-system-inhibitor (RAASi)-related hyperkalemia was associated with significantly lower levels of potassium in serum and hyperkalemia-related adverse events as well higher, guideline-directed RAASi use [76]. This evidence concerns the gene REN and Hyperkalemia.